Biosino Bio-Technology and Science Incorporation
Market Cap
HK$217.1m
Last Updated
2021/04/11 10:16 UTC
Data Sources
Company Financials
Executive Summary
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products primarily in Mainland China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Imperfect balance sheet with questionable track record.
Share Price & News
How has Biosino Bio-Technology and Science Incorporation's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8247 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: Insufficient data to determine 8247's volatility change over the past year.
Market Performance
7 Day Return
-10.7%
8247
-3.1%
HK Biotechs
-1.1%
HK Market
1 Year Return
-10.7%
8247
59.2%
HK Biotechs
28.6%
HK Market
Return vs Industry: 8247 underperformed the Hong Kong Biotechs industry which returned 59.2% over the past year.
Return vs Market: 8247 underperformed the Hong Kong Market which returned 28.6% over the past year.
Shareholder returns
| 8247 | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.7% | -3.1% | -1.1% |
| 30 Day | -10.7% | 2.0% | -1.8% |
| 90 Day | -10.7% | 7.1% | 3.4% |
| 1 Year | -10.7%-10.7% | 59.5%59.2% | 33.5%28.6% |
| 3 Year | -29.9%-38.8% | -32.1%-33.3% | 4.0%-6.9% |
| 5 Year | -52.2%-61.3% | -0.3%-4.0% | 48.7%23.7% |
Long-Term Price Volatility Vs. Market
How volatile is Biosino Bio-Technology and Science Incorporation's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Valuation
Is Biosino Bio-Technology and Science Incorporation undervalued compared to its fair value and its price relative to the market?
67.28x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 8247's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 8247's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 8247 is poor value based on its PE Ratio (67.3x) compared to the HK Biotechs industry average (40.5x).
PE vs Market: 8247 is poor value based on its PE Ratio (67.3x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8247's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8247 is good value based on its PB Ratio (1x) compared to the HK Biotechs industry average (3.4x).
Future Growth
How is Biosino Bio-Technology and Science Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
56.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosino Bio-Technology and Science Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Biosino Bio-Technology and Science Incorporation performed over the past 5 years?
-66.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8247 has a large one-off gain of CN¥9.2M impacting its December 31 2020 financial results.
Growing Profit Margin: 8247 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 8247 has become profitable over the past 5 years, growing earnings by -66.2% per year.
Accelerating Growth: 8247 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 8247 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (17.5%).
Return on Equity
High ROE: 8247's Return on Equity (-0.4%) is considered low.
Financial Health
How is Biosino Bio-Technology and Science Incorporation's financial position?
Financial Position Analysis
Short Term Liabilities: 8247's short term assets (CN¥386.5M) exceed its short term liabilities (CN¥378.9M).
Long Term Liabilities: 8247's short term assets (CN¥386.5M) exceed its long term liabilities (CN¥49.5M).
Debt to Equity History and Analysis
Debt Level: 8247's debt to equity ratio (97.7%) is considered high.
Reducing Debt: Insufficient data to determine if 8247's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 8247's debt is not well covered by operating cash flow (5.9%).
Interest Coverage: Insufficient data to determine if 8247's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Biosino Bio-Technology and Science Incorporation current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 8247's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8247's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8247's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8247's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 8247 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8247's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Yanglin Lin (38 yo)
0.67
Tenure
Mr. Yanglin Lin serves as the President of Biosino Bio-Technology and Science Incorporation since August 3, 2020. He serves as the executive director of New Journey Hospital Group Co., Ltd since February 2...
Leadership Team
Experienced Management: 8247's management team is considered experienced (2.9 years average tenure).
Board Members
Experienced Board: 8247's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biosino Bio-Technology and Science Incorporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biosino Bio-Technology and Science Incorporation
- Ticker: 8247
- Exchange: SEHK
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$217.061m
- Shares outstanding: 144.71m
- Website: https://www.sinobio.com.cn
Number of Employees
Location
- Biosino Bio-Technology and Science Incorporation
- No. 27, Chaoqian Road
- Science and Technology Industrial Park
- Beijing
- 102200
- China
Listings
Biography
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products primarily in Mainland China. It offers clinical c...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 10:16 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.